Clinical Trial Update: MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

This entry notes an ongoing Phase 1 trial evaluating an MK2 inhibitor in combination with mFOLFIRINOX for untreated metastatic pancreatic ductal adenocarcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• MK2 inhibitor
• mFOLFIRINOX

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Status: RECRUITING